T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Applied Materials
AMAT
$435B
| $1.38B | 0.15% |
5,384,256
+840,486
| +18% | +$201M |
|
127
Lattice Semiconductor
LSCC
$18.4B
| $1.33B | 0.14% |
18,087,750
+6,676
| +0% | +$475K |
|
128
US Bancorp
USB
$101B
| $1.33B | 0.14% |
24,919,079
+4,153,080
| +20% | +$204M |
|
129
Republic Services
RSG
$65.6B
| $1.33B | 0.14% |
6,268,900
-76,320
| -1% | -$16.4M |
|
130
L3Harris
LHX
$54.1B
| $1.32B | 0.14% |
4,492,649
-1,478,900
| -25% | -$427M |
|
131
AutoZone
AZO
$49.7B
| $1.31B | 0.14% |
387,042
+7,390
| +2% | +$27.9M |
|
132
CVS Health
CVS
$121B
| $1.3B | 0.14% |
16,443,986
-953,749
| -5% | -$75.2M |
|
133
Accenture
ACN
$110B
| $1.28B | 0.14% |
4,773,467
+582,719
| +14% | +$148M |
|
134
Ross Stores
ROST
$79.6B
| $1.26B | 0.14% |
7,012,501
-259,790
| -4% | -$43.4M |
|
135
Entegris
ENTG
$24.6B
| $1.23B | 0.13% |
14,656,565
-688,213
| -4% | -$59.8M |
|
136
Zimmer Biomet
ZBH
$18.7B
| $1.23B | 0.13% |
13,631,819
-1,450,619
| -10% | -$138M |
|
137
Dollar Tree
DLTR
$24.7B
| $1.2B | 0.13% |
9,785,453
-489,053
| -5% | -$52.4M |
|
138
Equity Residential
EQR
$24.2B
| $1.19B | 0.13% |
18,897,519
-969,726
| -5% | -$59.5M |
|
139
Progressive
PGR
$121B
| $1.19B | 0.13% |
5,213,427
+93,120
| +2% | +$21M |
|
140
Prologis
PLD
$134B
| $1.19B | 0.13% |
9,294,148
-453,480
| -5% | -$56.5M |
|
141
Sherwin-Williams
SHW
$87.4B
| $1.18B | 0.13% |
3,631,197
-5,227,671
| -59% | -$1.75B |
|
142
Equinix
EQIX
$105B
| $1.13B | 0.12% |
1,477,273
-50,273
| -3% | -$39.4M |
|
143
Fortive
FTV
$18.6B
| $1.11B | 0.12% |
20,046,352
+4,532,031
| +29% | +$235M |
|
144
Atmos Energy
ATO
$28.7B
| $1.11B | 0.12% |
6,597,064
-1,220,132
| -16% | -$211M |
|
145
Rexford Industrial Realty
REXR
$8.11B
| $1.1B | 0.12% |
28,336,003
+667,594
| +2% | +$27.5M |
|
146
Coupang
CPNG
$29.3B
| $1.09B | 0.12% |
46,407,946
-14,989,559
| -24% | -$426M |
|
147
Quest Diagnostics
DGX
$26.2B
| $1.09B | 0.12% |
6,297,157
-708,833
| -10% | -$129M |
|
148
Vertiv
VRT
$111B
| $1.09B | 0.12% |
6,730,205
-391,104
| -5% | -$67.9M |
|
|
EXE
149
Expand Energy Corp
EXE
$22.3B
| $1.07B | 0.12% |
9,670,165
-1,203,160
| -11% | -$133M |
|
150
Synopsys
SNPS
$79B
| $1.04B | 0.11% |
2,218,172
-1,106,267
| -33% | -$491M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.